Medication info

Evans Injection (Sodium Ibandronate Dihydrate)

Prescription medicationInjectionsIntravenous injectionExpired
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Hanpoong Pharmaceutical Co., Ltd.
Appearance
This injection is a colorless and transparent solution contained in a colorless, transparent glass prefilled syringe, supplied with a single-use needle.
Packaging
3 milliliters/prefilled syringe
Approval status
Expired

MFDS item code 201905932 · Notified 2019.08.22

This product's status changed to Expired on 2024.08.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or less or creatinine clearance of 30ml/min or more. Administration of this drug is not recommended for patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.
Child administration
Efficacy and safety in children aged 18 years or younger have not been studied.

Ingredients

Manufacturer
Hanpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis that may occur in postmenopausal women. Osteoporosis is a condition where the strength of bones decreases, leading to an increased risk of fractures. This medication helps strengthen bones and maintain bone density, reducing the risk of fractures. Therefore, it is an appropriate treatment for those experiencing difficulties with bone health due to menopause.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment with serum creatinine of 200 µmol/L(2.3mg/dL) or less or creatinine clearance of 30ml/min or more. Administration of this drug is not recommended for patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.

Child administration

Efficacy and safety in children aged 18 years or younger have not been studied.

Precautions

This medication must be administered intravenously, and great caution is required as administering it intra-arterially or around veins may cause tissue damage. Patients who are allergic to this drug or its components, or have untreated hypocalcemia, should not use this medication. During treatment with this drug, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, as well as musculoskeletal symptoms such as musculoskeletal pain, arthralgia, and myalgia may occur. Moreover, flu-like symptoms such as fever, chills, fatigue, arthralgia, and myalgia may temporarily occur, most often resolved without interruption of treatment at mild to moderate levels. Among patients receiving this drug, rare reports of skin rash, headaches, and fatigue have been recorded. Rarely, bisphosphonate therapy may lead to osteonecrosis of the jaw, particularly in cancer patients or those receiving dental treatment. It is advisable to undergo oral examination before receiving this drug and to avoid excessive dental procedures during treatment. Osteonecrosis of the external auditory canal has also been reported rarely; consult a physician if there is any ear pain or discharge. During osteoporosis treatment, severe bone, joint, or muscle pain may arise, and it is crucial to inform healthcare providers immediately if such symptoms occur. Patients using this drug for an extended period may experience atypical femoral fractures, so immediate evaluation is essential if pain arises in the thigh or groin. When using this drug, adequate intake of calcium and vitamin D is necessary, and usage should be considered after treatment in cases of hypocalcemia or bone metabolism disorders. This drug is primarily excreted through the kidneys without being metabolized in the liver, so patients with poor kidney function should undergo regular monitoring. Its safety has not been established during pregnancy or breastfeeding; therefore, avoiding its use is recommended. In cases of overdose, renal and liver function should be closely monitored, and appropriate treatment should be administered if hypocalcemia or other electrolyte imbalances occur. This medication should not be mixed with calcium-containing solutions and must only be administered intravenously. After use, the injection needle and syringe should not be reused and should be safely disposed of.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical femoral and intertrochanteric fractures, dizziness, optic atrophy, lower motor neuron disease lesions, tremor, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin exfoliation, sensory impairment

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air and kept at room temperature between 1°C and 30°C. Proper storage maintains the drug's efficacy and safety.

Appearance and packaging

Appearance

This injection is a colorless and transparent solution contained in a colorless, transparent glass prefilled syringe, supplied with a single-use needle.

Package unit

3 milliliters/prefilled syringe

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.